SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. (“Eastbourne”) today announced that on January 30, it notified Amylin Pharmaceuticals, Inc. (“Amylin”) (NASDAQ: AMLN) of its intention to nominate a minority slate of five highly qualified individuals for election to the 12 member Board of Directors at the Company’s 2009 Annual Meeting of Shareholders. The nominees are Dr. Kathleen Behrens, Marina Bozilenko, Charles Fleischman, William Nuerge and Jay Sherwood. Eastbourne currently owns approximately 12.5% of Amylin’s outstanding shares.
